BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN), today announced that it has initiated a pivotal trial of SGN-35 for patients with relapsed or refractory Hodgkin lymphoma. The trial is being conducted under a Special Protocol Assessment (SPA), which is an agreement between the U.S. Food and Drug Administration (FDA) and Seattle Genetics regarding the trial design necessary to support an efficacy claim in a New Drug Application (NDA). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
